Asthma is a complex chronic disease associated with high health care costs and poor quality of life yet is treatable and manageable. Despite advances in respiratory care, asthma affects over 24 million people in the U.S. In 2020, patients with asthma accounted for nearly one million emergency department visits. Part of the reasons for these unplanned events associated to uncontrolled disease was lack of specialist visits; 62% of severe asthma patients have no specialist visits in a 2-year period and some patients could wait at least a year to some over 5 years to see a specialist. A comprehensive and coordinated approach is needed to reshape the care paradigm for this chronic respiratory disease patients with significant disparity in their care experience and outcomes.

Sponsored by AstraZeneca, this panel will share unique perspectives addressing the key changes needed in the policy, care delivery design, quality standards, personal, and clinical barriers that impact people with asthma across their lifespans.

You will learn about:

• Guideline-directed medical therapies and a time-clock pathway for asthma-control assessment and management. New directions in guideline directed therapy as well as the interactions of therapeutic interventions, delivery systems and policy
• Opportunities to support patients and clinicians with self-management action planning.
• Quality accountability approaches such as measures or standards that can drive improved outcomes for patients with asthma

Made possible through the generous support of our Diamond Sponsor: